menu
    • menu

    Company profile for Ashibio

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Willow Birch Pharma delivers trusted, high-quality APIs nationwide with unmatched service, compliance, and competitive value.

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Āshibio is focused on developing innovative therapies for bone and connective tissue disorders, particularly targeting conditions like Heterotopic Ossification (HO) and Fibrodysplasia Ossificans Progressiva (FOP). These diseases involve abnormal bone formation in soft tissues, with FOP being a rare genetic disorder that causes progressive HO from early childhood. Āshibio aims to prevent symptom onset and slow disease progres...
    Āshibio is focused on developing innovative therapies for bone and connective tissue disorders, particularly targeting conditions like Heterotopic Ossification (HO) and Fibrodysplasia Ossificans Progressiva (FOP). These diseases involve abnormal bone formation in soft tissues, with FOP being a rare genetic disorder that causes progressive HO from early childhood. Āshibio aims to prevent symptom onset and slow disease progression with novel treatments.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    AshibioUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    2000 Sierra Point Parkway, Brisbane
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://ashibio.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Ashibio Reveals Encouraging Preclinical Data for Bone Disorders
    Ashibio Reveals Encouraging Preclinical Data for Bone Disorders

    08 Sep 2025

    // PHARMAWEB

    https://www.pharmiweb.com/press-release/2025-09-08/?shibio-reports-promising-preclinical-data-for-two-first-in-class-antibodies-targeting-debilitating

    PHARMAWEB
    08 Sep 2025
    Share Share
    ?shibio Expand Pipeline With Vantictumab for Osteopetrosis Type 2
    ?shibio Expand Pipeline With Vantictumab for Osteopetrosis Type 2

    19 Aug 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250819210349/en/shibio-Expands-Clinical-Pipeline-with-Vantictumab-a-First-In-Class-Antibody-for-Autosomal-Dominant-Osteopetrosis-Type-2

    BUSINESSWIRE
    19 Aug 2025
    Share Share
    ?shibio Starts Ph1b SCI Trial of Andecaliximab for HO Risk
    ?shibio Starts Ph1b SCI Trial of Andecaliximab for HO Risk

    24 Jun 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250610649423/en/shibio-Doses-First-Patient-in-Phase-1b-Trial-of-Andecaliximab-in-Patients-with-Spinal-Cord-Injury-SCI-at-Risk-of-Heterotopic-Ossification-HO

    BUSINESSWIRE
    24 Jun 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search